Summary. -Q fever is a highly infectious, widespread airborne zoonosis caused by Coxiella burnetii bacterium. Humans usually acquire the disease by inhalation of contaminated aerosol produced by infected livestock. Vaccination is the most practical way for prevention and control of the disease in the exposed population. In this work, we reviewed the most important Q-fever outbreaks in Slovakia as well as the progress in vaccine development. One of them represents a soluble antigen complex produced by extraction with trichloroacetic acid from a highly purified C. burnetii phase I strain Nine Mile. It was developed at the Institute of Virology in Bratislava. The protein content of this vaccine was separated by gel electrophoresis and analyzed by mass spectrometry. The study has resulted in the identification of 39 bacterial proteins from which 12 were recognized as immunoreactive. Most of the proteins were involved in bacterium pathogenicity (41.6%) and cell wall maintenance (25%). Four of the immunoreactive proteins may possess the moonlighting activity. Definition of the vaccine components represents a prerequisite for vaccine standardization and approval by governmental authorities.
Introduction
Coxiella burnetii is the causative agent of Q fever, a worldwide zoonotic disease with considerable economic impact in the livestock industry. Domestic animals as cattle, sheeps, and goats are the main reservoirs of C. burnetii and the source of Q fever in human.
The human infection is acquired by inhaling aerosolized microorganisms produced by infected livestock. The acute infection is typically asymptomatic or manifests as a febrile flu-like illness or pneumonia followed by a spontaneous recovery. In a small percent, patients may develop meningoencephalitis, hepatitis, endocarditis that require intensive care. Chronic infection is usually accompanied by severe symptoms such as pulmonary infections, endocarditis or hepatitis.
In Europe, Q fever is widely extended, several outbreaks have been reported in Bulgaria, Germany, France, Hungary, and Poland. The largest outbreak arose between [2007] [2008] [2009] [2010] in the Netherlands which resulted in 4026 human cases (Van der Hoek et al., 2010; Georgiev et al., 2013; Gyuranecz et al., 2014) .
The first outbreak of Q fever in Slovakia was recognized in 1954 among agricultural workers. Epidemiological investigations revealed that the source of infection was a sheep flock imported from Romania. Shortly after, an infection of textile plant workers occurred (Rehacek, 1987) . During the next decades, many small epidemics were reported from factories processing imported wool or hides as well as from sheep and cattle farms with imported animals (Table 1) . Within the period of 1972-1982 large-scale vaccination of the ruminants and their veterinary control were implemented, which resulted in significant reduction of Q fever cases in the country (Kováčová et al., 2002) . Varga et al. (1997) 1993, Rimavská Sobota District 11 farmworkers Goats (abortion) Varga et al. (1997 ) 2007 Veterinary students (≥1:800 IgG in 20 students = 8.2 %)
Professionally exposed Dorko et al. (2008) The largest outbreak of human Q fever in Slovakia began as a result of imports of 1181 goats from Bulgaria in September 1992. They were temporarily housed at Rimavská Sobota District, and 500 of them were transferred in January 1993 to the farm in the village Jedľové Kostoľany, Nitra District (Dorko et al., 2012; Varga, 1997) . Within the next two months, several abortions occured which resulted in two outbreaks. During the first one, 11 humans who were in direct contact with animals were infected (Dorko et al., 2012) . The second epidemic, however, involved as many as 113 human cases (Table 1 ). Epidemiological investigations revealed that the source of infection was a contaminated aerosol in a local pub that arose from the clothing of farm workers who witnessed the abortion of one of the goat shortly before (Kováčová et al., 1998; Varga, 1997; Rehacek et al., 1996) . Q fever outbreaks usually occur from occupational exposure involving veterinarians, meat processing plant workers, dairy workers, livestock farmers, and laboratory personnel working with C. burnetii. Thus, prevention and control efforts should be directed primarily toward these groups and environments. The most efficient way of avoidance is a vaccination of the exposed populations. Although clinical data are lacking, vaccination should also be considered for persons who are at higher risk for development of chronic Q fever, including those with cardiac valve defects or prostheses, those with vascular aneurysms, and immunocompromised patients. Therefore, development of an effective vaccine against Q fever with minimal adverse reactions become a subject of interest to many researchers.
One of the first vaccines was prepared in 1948, only 12 years after the discovery of C. burnetii. This early whole cell vaccine (Smadel vaccine) was developed from formalinkilled and ether-extracted C. burnetii, containing 10% yolk sac debris (Waag et al., 2002) . Later, it was observed, that purification with the aim to remove chicken proteins and lipids, and isolation of the whole inactivated bacterial cells (WCV), contributed to less reactogenic and highly immunogenic preparations (Waag, 2007) . Hendrix and Chen (2012) also showed that the vaccines prepared from virulent phase I microorganisms (WCV-PI) are more effective than the attenuated phase II vaccines (Arricau-Bouvery and Rodolakis, 2005). Nevertheless, this WCV was banned in the most countries around the world due to the prevalence of adverse effects (local and systemic reactions) that may occur in people with a history of Q fever or those that were previously vaccinated (Waag et al., 2007) . Q-Vax® is the only commercially available human Q fever WCV-PI vaccine which is licensed in Australia. It is a monovalent vaccine developed in 1989 by the Commonwealth Serum Laboratories from formalin-inactivated purified whole cells of phase I C. burnetii Henzerling strain (Porter et al., 2011) . It has a reported efficacy over 98 % (Trubiano et al., 2012; Sellens et al., 2016; Waag et al., 2002) with protection up to 5 years (Ruiz and Wolfe, 2014) . However, according to the rules of Australian National Vaccination Programme, strict pre-vaccination protocols such as serology and intradermal skin testing with diluted vaccine have to be implemented prior administration to avoid adverse effects (Sellens et al., 2016) .
The acellular vaccines, or chemovaccines, are a new generation of vaccines with reduced adverse reactions that were shown to be as effective against Q fever as the whole cell vaccine (Parker et al., 2006) . The chloroform-methanol residue vaccine (CMR) was prepared thanks to the cooperation of Rocky Mountain Laboratories with the US Army Research Institute for Infectious Disease in the late 70s. The phase I Henzerling strain inactivated with formalin was lyophilized and refluxed with a chloroform-methanol (4:1) mixture (Kersh et al., 2013) . The prepared vaccine was able to induce protection in animals and human volunteers (Oyston and Davies, 2011; Fries et al., 1993) . The chemovaccine, developed in former Czechoslovakia, is a soluble antigen complex produced by extraction of highly purified phase I C. burnetii Nine Mile strain EP3 using trichloroacetic acid (TCA). This extract contains proteins and LPS and it is highly reactogenic in humans (Kazar et al., 1982) . In laboratory animals (mice and rabbits) the TCA extract induces the formation of antibodies against antigens 1 and 2, which was demonstrated by serodiagnosis as well as with opsonization phagocytosis and serum protective tests (Kazar et al., 1978) . It also induces the cell-mediated component of immunity (Kazar et al., 1983) . According to the record of the Department of Rickettsiology, Institute of Virology, BMC SAS, there were two major periods of immunization using this vaccine. The first was from 1972 to 1982 and the second from 1986 to 2004 during which 1421 and almost 300 individuals were vaccinated, respectively. They were mainly veterinarians, laboratory, farm and abattoir workers, and soldiers (Kazar et al., 1982 (Kazar et al., , 1983 . While significant protective efficacy and antibodies response were observed in the vaccinated individuals, no significant side effects were noted. Very mild systemic and local adverse reactions were described only in previously exposed individuals. Nevertheless, the vaccine production was stopped in 2002 due to insufficient knowledge of the composition of the vaccine. To fill the knowledge gap, we performed comprehensive characterization of the protein composition of the TCA extract.
Material and Methods
Preparation of the TCA extract of C. burnetii RSA 493. The optimal condition of extraction by TCA was applied (Lukacova et al., 1989) . The purified inactivated C. burnetii RSA 493 phase I cells (100 mg) were resuspended in 20 ml of Mill-Q H 2 O and 30 ml of 16.7 % (w/v) TCA solution was added to obtain the final concentration of 10 % (w/v) of TCA. The extraction was performed at 0°C for 45 min in an ice bath containing NaCl under constant stirring. After neutralization with sodium hydroxide, the mixture was spun down at 16,000 x g and 4°C for 40 min. Three drops of 10% (v/v) phenol was added to avoid microbial contamination. The supernatant was then dialyzed using 3,000 MW cut off membrane for 3 days against Mill-Q H 2 O water (2 l changed once a day) at 4°C. This step was necessary to remove the salt. Then the sample was frozen at -80 o C followed by lyophilization for 3 days using Power dry PL3000 instrument (Thermo Scientific).
Two dimensional electrophoresis . Aliquots (500 µg) of the lyophilized extract were dissolved in a sample buffer (8 mol/l Urea, 2 mol/l thiourea, 1% (v/v) ASB14, 1% (w/v) Triton X-100) containing 1% (v/v) of carrier ampholytes pH range 3-10 or 4-7 (GE Healthcare), and 1.7% of DeStreak reagent (GE Healthcare). Immobilized pH gradient strips (pH 3-10 or pH 4-7, 18 cm, GE Healthcare, Sweden) were passively rehydrated overnight (approx. 16 h) in the dark at RT, then placed into Multiphor II apparatus (GE Healthcare, Sweden) and isoelectric focusing was performed using the following protocol; 100V in gradient for 1 h, 500V in gradient for 1 h, 1000V in gradient for 1 h, 6,000V in gradient for 3 h, and 6,000V for 18 h. The strips were then rinsed in deionized water and incubated in equilibration buffer (50 mmol/l Tris-HCl, pH 8.8, 6 mol/l urea, 30% (v/v) glycerol, 2% (w/v) SDS containing 1% (w/v) dithiothreitol (DTT, Sigma-Aldrich)) for 15 min, followed by 4% (w/v) iodoacetamide (IAA, Sigma-Aldrich) with 0.08% (w/v) bromphenol blue. The second dimension separation was carried out on 16% polyacrylamide gels (20 cm x 20 cm x 1 mm) in Tris-glycine running buffer, using a Protean XL (Bio-Rad, USA) device. It was performed at 5 mA/gel for 60 min, followed by 45 mA/gel until tracking dye migrated to the bottom of the gels. Protein spots were visualized with colloidal Coomassie Brilliant Blue (CBB) or used for Western blot.
Western blot. After the electrophoresis, the gel was washed for 5 min in Milli-Q water. A PVDF membrane 0.22 µm (Merck, Germany) was activated with methanol, and the proteins were transferred using a semi-dry blotting apparatus (Multiphore II, Amersham). The voltage was set according to gels size (surface area (cm 2 ) * 0.8). The membrane was blocked with 5% non-fat dry milk (Biorad) in PBS-Tween 0.1% (PBS-T) overnight at 4°C. Then, it was five times washed with PBS-T and incubated for 2.5 h in 1:200 diluted rabbit serum containing polyclonal antibody (to the Phase I & II C.burnetii antigens) in 2.5% non-fat dry milk at room temperature (RT). The membrane was washed 5 times for 5 min with 200 ml of PBS-T and incubated with secondary antibody (IgG HRP-linked 1:1,500 Polyclonal Swine, Anti-Rabbit Immunoglobulin, Dako) for 1 h in 2.5% non-fat dry milk in PBS-T at RT. Finally, the membrane was washed five times with PBS-T and developed by ECL system (GE Healthcare).
Trypsin digestion and mass spectrometry analyses. The excised spots were washed with agitation in 50% (v/v) acetonitrile (ACN) (Merck, Germany) in 50 mmol/l NH 4 HCO 3 (Ambic; Fluka,) at RT. After complete destaining, gel pieces were dehydrated with 100% ACN for 10 min at RT, reduced in 10 mmol/l DTT, and alkylated with 50 mmol/l iodoacetamide. The gel plugs were washed and dehydrated again with 100% ACN, and then incubated for 14-16 h at 37°C in digestion solution (10 ng/µl of lyophilized sequencing grade modified trypsin (Promega, USA). The resulting peptides were acidified in extraction solution (1% (v/v) formic acid (FA, Sigma Aldrich) in 5% (v/v) ACN) followed by dehydration of the gel pieces in 70% ACN. The tryptic peptides were analyzed by automated nanoflow reversephase chromatography using the nanoAcquity UPLC system coupled to a Q-TOF Premier (Waters, UK) as described earlier (Skultety et al., 2011) . The data were processed using the ProteinLynx Global Server (PLGS) v. 3.0 (Waters, UK). All data were lock spray calibrated against [Glu1]-Fibrinopeptide B (Sigma Aldrich, USA). The results were searched against the full proteome sequences derived from C. burnetii Nine Mile phase I which was downloaded from UniProt (in October 2016). Tentative peptide and protein identifications were ranked, and scored by their relative correlation to a number of wellestablished models of known and empirically derived physicochemical attributes of proteins and peptides. During database searches, one missed cleavage site was allowed. The precursor peptide mass tolerance was set to ± 20 ppm, and fragment mass tolerance to ± 40 ppm. The search was performed with Cys carbamidomethylation and Met oxidation as fixed and variable modifications, respectively.
A minimum of two matched peptides and three or more consecutive fragment ions from the same series were required for protein identification. Protein identifications were accepted after manual inspection of probabilistic based PLGS assignment at 95% confidence level. Only those proteins are listed in the tables which were found at least twice out of three replicates.
Results and Discussion
In order to reveal protein composition of the soluble antigen used as a chemovaccine, the purified C. burnetii cells in phase I was subjected to extraction with TCA. The proteins were then resolved within the pI range 3-10 and mass range 15-150 kDa using 2-DE. The analyses were performed on samples prepared in two biological replicates. A representative gel is shown in Fig. 1a . Image analysis revealed 82 protein spots which were reproducibly detected on CBB-stained gels.
The protein spots were excised from the gels, digested with trypsin, and analyzed by LC-MS/MS. Subsequently, data were processed by PLGS and the experimentally recorded MS spectra matched against the fully sequenced C. burnetii Nine Mile phase I database. Specifically, 39 proteins were identified ( Table 2 ). The 10 kDa chaperonin was found in six (4, 5, 70, 71, 72, 73) spots, the hypothetical exported protein CBU_1095 was identified in five (14, 16, 17, 58, 59 ) spots, and the Tol system periplasmic component ybgF (52, 53, 54, 62), uncharacterized protein CBU_0089a (12, 19, 71, 72) , and 50S ribosomal protein L7/L12 (6, 7, 74, 75) in four spots. The others were recognized in less than 3 spots. Most of the identified proteins (42%) were associated with cytoplasm, 17% with the periplasm, 8% with the inner membrane, and 33% with the outer membrane of the bacterium (Fig. 2a) . Interestingly, as many as 41% of the identified immunoreactive proteins may have moonlighting activity. 
(a) (b)
The function was assigned to all identified proteins using UniProt database and then sorted into four groups (Fig. 2b) . Proteins involved in pathogenicity & pathogenesis were the most frequent (41.66%), the second group corresponds to the cell envelope maintenance (25%), followed by metabolic pathways (16.66%). The last group is formed by proteins involved in protein & peptide secretion and trafficking (8.3%) (Fig. 2b) .
Immunoblot analysis detected 12 immunoreactive proteins (Fig. 1b, Table 2 ). Interestingly, four of them may have moonlighting activity. All these proteins have been previously reported in other studies (Flores-Ramirez et al., 2017; Papadioti et al., 2011; Sekeyova et al., 2009; Beare et al., 2008; Jian et al., 2014 , Toman et al., 2013 . These include the general markers for Q fever chaperones 60 kDa (Groel) and the chaperonin dnaK ( Xiong et al 2012) as well as the virulent factors (ompH and Mip), markers for acute Q fever (the omp's AdA and com1), and another stress protein with moonlighting activity (superoxide dismutase [Fe] sodB) that are involved in pathogenesis and pathogenicity (Flores-Ramirez et al., 2014; Skultety et al., 2011) . The component of the tol-pal system ybgF which mediates the peptidoglycan synthesis and outer membrane constriction during cell division (Deringer et al., 2011) and the marker of acute Q fever (omp-A like protein CBU_0307) participate in the stabilization and maintenance of the cell envelope. The secB is engaged in protein trafficking. The glycine cleavage system protein H (gcvH), malate dehydrogenase (mdh), and fructose-bisphosphate aldolase (fabA) are metabolic enzymes. The last one is involved in the glycolysis and gluconeogenesis with virulence function in several bacteria (Shams et al., 2014) .
Conclusion
In this work proteomic approach based on 2-D electrophoresis, mass spectrometry, and bioinformatics was employed to identify and characterize the protein composition of the soluble antigen possessing phase I antigen reactivity that was used as a chemovaccine against Q fever in men. It was successfully administered in the past to more than 1700 volunteers. The vaccine was prepared from C. burnetii cells of strain Nine Mile EP3 in phase I using TCA extraction under the optimal conditions. The proteomic analysis resulted in the identification of 39 unique proteins of C. burnetii from which 12 were recognized as immunoreactive. The localization and function of these proteins were assigned by bioinformatics. It was suggested that the identified proteins are primarily extracted from the surface of the C. burnetii cells. These proteins may form a part of the active components of the vaccine, which challenges the immune system of the host to generate antibodies that can fight the disease. Nevertheless, further studies have to be performed to analyze the proteins and the saccharide moiety of the extract which is involved in inducing protection. Because, some proteins, if included in the vaccine, may be immunosuppressive, whereas in other cases immune responses to some proteins may actually enhance disease. Thus, it is critical to identify those proteins that are essential for inducing protection and eliminate the others.
